Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2015

  • ID: 3169855
  • Report
  • 101 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • ReGenX Biosciences, LLC
  • Sanofi
  • MORE
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2015

Summary

This, ‘Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2015’, provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • ReGenX Biosciences, LLC
  • Sanofi
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview
Therapeutics Development
Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Overview
Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Development by Companies
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Investigation by Universities/Institutes
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Development by Companies
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Investigation by Universities/Institutes
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Companies Involved in Therapeutics Development
Aegerion Pharmaceuticals, Inc.
Amgen Inc.
Cerenis Therapeutics Holding SA
CymaBay Therapeutics, Inc.
Merck & Co., Inc.
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
ReGenX Biosciences, LLC
Sanofi
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AEM-28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alirocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-0010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anacetrapib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bococizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BSN-272 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CER-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evinacumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evolocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate LDL Receptor for Homozygous Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lomitapide mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBX-8025 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mipomersen sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Recent Pipeline Updates
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Product Development Milestones
Featured News & Press Releases
Jan 28, 2015: Aegerion Investigated by Former Louisiana Attorney General and Special Prosecutor Richard P. Ieyoub and the Firm of Ieyoub O’Bell & Myers
Nov 18, 2014: Genzyme And Isis Present KYNAMRO Clinical Data At The American Heart Association
Sep 02, 2014: Isis Pharmaceuticals Presents Data On KYNAMRO At European Society of Cardiology Congress 2014
Sep 02, 2014: Isis Pharmaceuticals Presents Data On KYNAMRO At European Society of Cardiology Congress 2014
Aug 27, 2014: Aegerion Pharmaceuticals Announces Resolution of Warning Letter for JUXTAPID Capsules
Jun 02, 2014: Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS
May 08, 2014: Genzyme and Isis Receive Corporate Award from the National Organization for Rare Disorders for the Development of KYNAMRO
Apr 09, 2014: Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
Mar 27, 2014: Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H1 2015
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Aegerion Pharmaceuticals, Inc., H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Amgen Inc., H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Cerenis Therapeutics Holding SA, H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by CymaBay Therapeutics, Inc., H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Merck & Co., Inc., H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Pfizer Inc., H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by ReGenX Biosciences, LLC, H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Sanofi, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics - Recent Pipeline Updates, H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects, H1 2015
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H1 2015
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Aegerion Pharmaceuticals, Inc.
- Amgen Inc.
- Cerenis Therapeutics Holding SA
- CymaBay Therapeutics, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- ReGenX Biosciences, LLC
- Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll